Hasten Biopharmaceutic Co., Ltd.

In 2023, China was the second largest product/technology exporter in the global biopharmaceutical pipeline, with 143 pipeline transactions, runner up only to the US. In China’s biopharmaceutical indus

Since its founding in 2020, Chinese firm Hasten Biopharmaceutic Co., Ltd. has doubled down on the growing cardiovascular market in the greater China region. In September, the Hefei, Anhui-headquarte

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Hasten Gets Greater China Rights T

Venture capital fundraising by biopharmaceutical companies has been a mixed bag so far in 2023, with a slow start to the year but a relative surge in big financings in March and April. There were only